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The World Health Organization added snakebite to the list of Neglec­
ted Tropical Diseases in 2009. Each year, snakebite affects the lives of 
around 4.5 million people worldwide, seriously injuring 2.7 million 
men, women and children, and claiming some 125 000 lives.[1]
Namibia is one of the most sparsely populated countries in 
the world (population 2.5 million) and home to an abundance of 
wildlife, including snakes.[2] There is no official database on snakebite 
in Namibia. The Namibian Snakebite Interest Group (NSIG) is 
involved with ~10 ­ 20 zebra snake (Naja nigricincta nigricincta) 
envenomations annually (PJCB and ELS, members of NSIG, personal 
communication; Francois Theart, official snake rescue and anti­
poaching agent, personal communication).
N. n. nigricincta is a spitting cobra and is frequently encountered 
in Namibia. The distribution is mainly the central and northern 
regions of this country, and southern Angola.[3] The snake seems to 
be well adapted to populated areas, and it appears to lack any fear of 
humans.[4]
As a result of 43 years of clinical involvement with snakebites in 
Namibia and clinical management of ~700 zebra snake bites, PJCB 
makes the following statements (personal communication): ‘This 
spitting cobra has come to be particularly feared, especially by the 
rural communities, as the snake is nocturnal and commonly found 
inside dwellings in search of small rodents for prey. The majority of 
N. n. nigricincta bites have occurred at night while the victims were 
asleep. Although rarely fatal, the venom is highly cytotoxic with 
no neurotoxic symptoms or signs observed.[5] Antivenom seems 
to be ineffective in the treatment of envenomation. Without early, 
adequate, speedy surgical debridement, necrosis with extensive tissue 
loss, contractures, disfigurement and loss of function will almost 
always be the outcome. The only exception being bites in the face 
or genital areas, where a more conservative surgical approach seems 
merited.’
No clinical research on N. n. nigricincta bites has been done. 
Treatment in Namibia has been derived from the clinical experience 
mentioned above. It was supported by studies by Warrell et al.[6] on 
bites by N. nigricollis, a very close relative of N. nigricincta found 
in central Africa, with a remarkably similar symptom complex and 
outcome.[6]
The Namibian experience and treatment stand in contrast with 
case studies done on N. mossambica.[7,8] This spitting cobra is found 
in the more tropical regions of southern Africa, northern Namibia 
and southern Angola.[9] Although envenomation causes severe tissue 
necrosis with occasional drowsiness and respiratory depression, 
antivenom seems to be effective if given shortly after the bite, 
and delayed surgical intervention is advocated. [7,8] The venom of 
N.  mossambica is used in the production of our currently available 
polyvalent antivenom from South African Vaccine Producers 
(SAVP),[10] which may explain why the antivenom, given early, results 
in less necrosis. The venom of N. n. nigricincta is not used in the 
manufacturing of the South African Institute for Medical Research 
(SAIMR) polyvalent antivenom.[10]
The severe cytotoxic effects and debilitating consequences of 
neglected bites of the zebra snake, as well as the lack of obvious 
systemic involvement in the majority of patients, have resulted in 
emphasis being placed on urgent treatment of the necrosis. However, 
over the years there have been a few marring reports of unexplained 
infant fatalities and renal failure following N. n. nigricinta bites.[11,12]
The authors have started renewed research on snakebites in 
Namibia, with the emphasis on N. n. nigricinta bites. The objective 
of this research is to establish evidence­based treatment protocols 
for all Namibian snakebites, especially those inflicted by N. n. 
nigricinta, and to compile a national snakebite database. During this 
research three patients were encountered who showed evidence of 
intravascular haemolysis, rhabdomyolysis and coagulopathy as well 
as severe tissue necrosis.
Case studies
Case 1
At 00h30 a zebra snake (N. n. nigricinta) bit a 23­year­old man 
in the face. He was asleep in his bed while staying at a lodge near 
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Etosha National Park. The patient was referred to the local snakebite 
specialist in Windhoek, where he arrived 7.5 hours after being bitten.
On admission he exhibited periorbital oedema, noticeably more 
severe on the right. Two fang marks, medial and inferior to the right 
eye with discoloration of the skin surrounding the fang marks and 
the upper eyelid, were noted. He complained of severe muscle pains 
in his back and legs.
On examination his vision and eye movements were normal. He 
was awake and orientated and showed no signs of muscle weakness, 
respiratory distress or cardiovascular compromise. Because he was 
stable, he was admitted to a general ward under the care of a general 
surgeon for initial conservative treatment and observation.
Laboratory results on day 1 were as follows: white blood cell 
count (WBC) 19.7 × 109/L (neutrophil count 17.2 × 109/L). The 
haemoglobin concentration (Hb) and urea and electrolytes (U&E) 
were normal. Unconjugated bilirubin was increased (57 µmol/L), 
with raised lactate dehydrogenase (LDH) (1 510 U/L), aspartate 
transaminase (AST) (675 U/L) and alanine transaminase (ALT) 
(86 U/L). Dipstick urinalysis showed 2+ blood in the urine.
On the second day a creatine kinase (CK) level was requested, 
which was elevated (96 900 U/L). LDH, AST and ALT were still 
high. Urine myoglobin and urine bilirubin were positive. Serum 
haptoglobin was very low (0.06 g/L) (normal 0.34 ­ 2.00 g/L).
The patient was treated with aggressive fluid management, 
analgesics and moxifloxacin (started on day 5). Although it is 
controversial, we give prophylactic antibiotics to all victims of 
cytotoxic snakebites. Studies in Taiwan and China underlined our 
clinical experience of a high incidence of secondary wound infections 
following cytotoxic bites, especially N. n. nigricincta bites, when no 
antivenom is given.[13­17]
The CK values peaked on day 3 (101 200 U/L) and gradually 
subsided over the following days. The international normalised ratio 
(INR), which peaked on day 2 (1.7), normalised without specific 
treatment. LDH peaked on day 3 (3 510 U/L). Hb decreased from 
16.3 g/dL (day 1) to 14.1 g/dL (day 7). The cumulative report is 
shown in Table 1. 
Kidney function and electrolyte values stayed within normal 
limits.
On day 9 the patient underwent surgical debridement by a plastic 
surgeon. Necrotic tissue was removed under the left eye and from 
the left upper eyelid. He recovered fully, underwent several more 
debridements, and had a skin graft on day 20.
Case 2
A 7­year­old boy was bitten on the face by a zebra snake, which 
also spat in his eyes, at 01h30 while asleep in his bed. He and his 
family were on holiday in Namibia, staying at a lodge in the north­
western part of the country. He was immediately taken to the 
local clinic, where his eyes were thoroughly rinsed with saline and 
where he erroneously received 10 mL SAVP polyvalent antivenom 
intravenously.
The patient was transferred to Windhoek, where he was admitted 
at ~11h00 under the care of the local snakebite expert. The bite was 
in the left infraorbital region, and severe bilateral periorbital oedema 
was present: he could not open his eyes. The swelling extended to the 
left side of the face and neck, with a 2 × 3.5 cm blue discoloured area 
of skin around the bite. He was fully awake and well orientated, but 
extremely irritable and complaining of severe muscle pains involving 
his entire body. His blood pressure, pulse rate, oxygen saturation and 
temperature were all within normal limits. There was no evidence 
of muscle weakness, but he exhibited signs of hyperaesthesia. Both 
lungs aerated well and there was no stridor or respiratory distress. An 
ophthalmologist was consulted.
Owing to concern of possible airway obstruction as a result of 
the severe swelling of the face and neck, the patient was transferred 
for observation to the intensive care unit (ICU). He was treated 
with maintenance intravenous fluids, amoxicillin­clavulanic acid, 
tilidine, paracetamol, diclofenac and dexamethasone. Blood samples 
for a full blood count, U&E, liver function tests (LFTs), CK and a 
clotting profile were sent to the laboratory, and dipstick urinalysis 
was requested.
Approximately 15 hours after having been bitten, the patient 
suddenly developed a sinus tachycardia (180 bpm), followed by 
a tonic­clonic convulsion. The convulsion lasted 5 minutes and 
terminated spontaneously. The patient was lethargic immediately 
after the convulsion, with increased peripheral reflexes and neck 
stiffness. An urgent CT scan showed no intracranial bleeding or 
structural abnormalities. At this stage a physician was consulted to 
join the team of specialists managing the patient. Intravenous sodium 
valproate was initiated. No further convulsions occurred and the 
tachycardia subsided spontaneously over the next hour.
Abnormal results of initial special investigations were as follows: 
dipstick urinalysis 3+ positive for blood, WBC 31.4 × 109/L (neutrophil 
count 25.4 × 109/L), INR 1.5 (normal 0.9 ­ 1.3), CK 2 090 U/L, AST 
118 U/L, unconjugated bilirubin 73 μmol/L and LD 793 U/L.
Table 1. Laboratory results, patient 1
Normal values Day 1 Day 2 Day 3 Day 4 Day 7 Day 9
Hb (13 ­ 18 g/dL 16.3 15.3 14.7 ­ 14.1 ­
WBC (4 ­ 11 × 109/L) 19.7 22.6 ­ ­ 17.7 ­
Neutrophils (2.75 × 109/L) 17.2 19.5 ­ ­ 11.7 ­
PLT (140 ­ 420 × 109/L) 191 212 194 ­ 337 ­
INR (0.9 ­ 1.3) ­ 1.7 ­ ­ ­ ­
PT (10.2 ­ 13.2 s) ­ 18.2 ­ ­ ­ ­
PTT (25.4 ­ 38.4 s) ­ 26.6 ­ ­ ­ ­
Unconjugated bilirubin (2 ­ 17 μmol/L) 57 ­ 25 ­ ­ ­
ALT (0 ­ 55 U/L) 86 ­ 301 316 ­ ­
AST (5 ­ 34 U/L) 675 ­ ­ ­ ­ ­
LDH (125 ­ 243 U/L) 1 510 ­ 3 510 2 260 ­ ­
CK (30 ­ 200 U/L) ­ 96 906 101 200 76 200 4 060 850
Hb = haemoglobin; WBC = white blood cell count; PLT = platelet count; INR = international normalised ratio; PT = prothrombin time; PTT = partial thromboplastin time;  
ALT = alanine transaminase; AST = aspartate transaminase; LDH = lactate dehydrogenase; CK = creatine kinase.
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The patient was kept in the ICU for monitoring of his vital signs. 
Intravenous fluids were pushed to maintain a urinary output of 2 mL/
kg/h. Vitamin K and fresh­frozen plasma were given preoperatively 
on day 2 and clindamycin was added. Daily special investigations 
(FBC, U&E, LFTs, CK and clotting profile) were done until the 
patient stabilised.
CK values increased until day 3 with a peak of 17 360 U/L. The 
INR peaked on day 2 (1.8) and the WBC decreased from 31.4 × 109/L 
on admission to 11.9 × 109/L on day 6.
Hb decreased from 15.1 g/dL on admission to 11.9 g/dL on day 7. 
Kidney function and electrolyte values stayed within normal limits. 
Cumulative results are shown in Table 2.
On day 3 a plastic surgeon performed debridement of all discernible 
necrotic tissue. Ophthalmological examination under anaesthesia 
revealed no injury to the left eye but a possible completely healed 
corneal lesion on the right, probably caused by the venom that had 
been spat into the eye. A further debridement with insertion of a 
Crawford tube into the left lacrimal duct was done on day 5. Spreading 
of the necrosis necessitated additional debridement on days 7 and 9. 
Swelling of the neck and face only started to resolve after day 5.
On day 10 the patient’s condition was considered stable and he was 
transferred to the care of a plastic surgeon in South Africa, where he 
had several more debridements and a skin graft.
Case 3
A 20­month­old baby was bitten on the left occiput by a zebra 
snake at 06h00 while sleeping on the floor at home, 15 km outside 
Okahandja, a small town 71 km north of Windhoek. The snake (a 
1.4 m juvenile male) was killed and brought along for identification. 
Prior to transfer to Windhoek, the patient erroneously received 
2 ampoules of SAIMR polyvalent antivenom at the local hospital.
The patient, irritable and with a raised pulse and blood pressure, 
arrived in Windhoek 10 hours after being bitten. The bite area was 
moderately swollen with blue discoloration. After being admitted 
under the care of a pediatrician in the ICU, an emergency debridement 
was done ~11 hours after the bite.
Initial blood results showed a low Hb (9.6 g/dL), a raised WBC 
(18.2 × 109/L) and neutrophilia (16.2 × 109/L). AST, ALT and LDH 
were elevated. Serum myoglobin was raised and the INR was 1.4. 
A  peripheral blood smear revealed polychromasia, burr cells and 
aniso­poikilocytosis (CK was not done on admission).
On day 2 the patient became drowsy, urine output dropped to 
<1 mL/kg/h, and the serum urea level increased to 8.6 mmol/L 
(normal 2.9 ­ 8 .2 mmol/L). This occurred in spite of aggressive 
fluid management. Furosemide was added. The INR increased to 3.2 
despite administration of fresh­frozen plasma and vitamin K. The Hb 
fell to 6.5 g/dL, and packed red cells were transfused.
During day 3, urine output responded to treatment and the INR 
normalised with further vitamin K and plasma. On the evening of 
day 3, the patient developed respiratory distress because of severe 
swelling. An emergency tracheostomy was performed and a large 
haematoma was drained from the bite area. The CK peaked on day 2 
at 75 000 U/L and was <500 U/L on day 8. LDH remained high 
until day 4 before starting to subside. Cumulative results are shown 
in Table 3. 
The patient required several debridements for a large necrotic area 
on the scalp. Skin grafts were done by a plastic surgeon after 2 weeks. 
All parameters returned to normal and the patient was discharged 
after 3 weeks.
Discussion
Snake venom is highly modified saliva that contains a complex 
mixture of proteins, enzymes and other substances with toxic and 
lethal properties. Envenomation can produce neurotoxic, cytotoxic, 
haemotoxic, myotoxic and cardiotoxic symptoms, presenting as a 
single symptom complex or in any combination, depending on the 
composition of the venom.[18,19]
The majority of recorded bites by N. n. nigricincta were inflicted on 
the victim’s extremities. The snake’s fangs are relatively short (~3 mm) 
with the venom opening proximal to the tip.[7] One can speculate 
that in a bite on an extremity, the venom is usually injected into the 
subdermal layer between the skin and muscle. Owing to the low 
vascularity of this area, minimal or no systemic absorption occurs 
and only necrotising signs may develop. Bites on the face, directly 
intravascular or in cases of high venom­to­body ratio (e.g. babies and 
small children) will result in venom absorption into the circulation 
with systemic envenomation.
Intravascular haemolysis occurs from snake envenomation as a 
result of the action of phospholipase A2, which is present in almost 
all snake venoms, and a basic protein called direct lytic factor, 
found only in elapid venoms.[19] With lysis of the red blood cells, 
haemoglobin is released into the bloodstream and is immediately 
bound by haptoglobin.[20] If the haemolysis is beyond the reabsorptive 
capacity of the haptoglobin, excess haemoglobin is filtered by the 
kidney and results in haemoglobinurea and urine haemosiderin.[21] 
Lysis of red cells causes anaemia[20] and haem promotes neutrophil 
Table 2. Laboratory results, patient 2
Normal values Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Hb (11.5 ­ 15.5 g/dL) 15.1 15.4 12.6 12.1 11.1 12.5 11.9
WBC (4.5 ­ 13.5 × 109/L) 31.4 28.8 19.3 16.6 ­ 11.9 ­
Neutrophils (1.5 ­ 8.5 × 109/L) 25.4 24.7 15.4 13.5 ­ 9.27 ­
PLT (140 ­ 420 × 109/L) 433 391 329 368 ­ 445 ­
INR (0.9 ­ 1.3) 1.5 1.8 1.4 1.0 ­ ­ ­
PT (10.2 ­ 13.2 s) 16.1 19.3 15.3 12.2 ­ ­ ­
PTT (25.4 ­ 38.4 s) 29.7 26.5 ­ ­ ­ ­ ­
Unconjugated bilirubin (2 ­ 17 μmol/L) 73 90 43 ­ ­ ­ ­
ALT (0 ­ 55 U/L) 35 53 99 ­ ­ ­ ­
AST (5 ­ 34 U/L) 118 328 510 ­ ­ ­ ­
LDH (100 ­ 295 U/L) 793 1 131 1 364 ­ ­ ­ ­
CK (30 ­ 200 U/L) 2 090 8 300 17 360 11 555 5 430 ­ 609
Hb = haemoglobin; WBC = white blood cell count; PLT = platelet count; INR = international normalised ratio; PT = prothrombin time; PTT = partial thromboplastin time;  
ALT = alanine transaminase; AST = aspartate transaminase; LDH = lactate dehydrogenase; CK = creatine kinase.
739       October 2019, Vol. 109, No. 10
IN PRACTICE
migration. Indicators of intravascular haemolysis are therefore low 
serum haptoglobin, haemoglobinuria, raised unconjugated bilirubin, 
falling haemoglobin values, markedly raised LDH, leukocytosis and 
schistocytes.[22­24]
Rhabdomyolysis is a common consequence of snake envenomation. 
Myotoxic phospholipases A2 in the venom bind to acceptors in 
the plasma membrane, initiating a series of complex degenerative 
events culminating in the dispersion of muscle constituents into the 
circulation.[25,26] Large quantities of potassium, phosphate, myoglobin, 
aldolase, CK, LDH, AST and purines leak into the circulation. 
Myoglobin in the renal filtrate can cause renal tubular damage by 
several mechanisms.[22,25,27­29] Proteases released from muscle injury 
cause hepatic dysfunction.[30] Hyperkalaemia, hypocalcaemia and 
hepatic inflammation are early complications, late complications 
being renal failure and diffuse intravascular coagulation probably 
caused by the activation of the clotting cascade by components 
released from the damaged muscles.[25,29]
Our patients exhibited leukocytosis, very high CK values (peaking 
2 ­ 3 days after the bite), raised serum myoglobin, low serum 
haptoglobin, raised AST, ALT and LDH, and an increased INR. Patient 
3 also exhibited polychromasia, burr cells and aniso­poikilocytosis on 
peripheral blood smears. A decrease in Hb was common.
A definitive diagnosis of rhabdomyolysis was made on the grounds 
of the serum CK being more than five times the normal value, and 
the presence of urine or serum myoglobin. The decrease in Hb, 
leukocytosis and peripheral smear features are more specific for 
haemolysis. Increased AST, LDH and unconjugated bilirubin, low 
serum haptoglobin and positive urine dipstick for blood overlap for 
both intravascular haemolysis and rhabdomyolysis.[21­23,25­36]
These rhabdomyolytic and intravascular haemolytic effects of N. n. 
nigricinta venom have not been recorded previously.[31] A recent study 
by Bittenbinder et al.[32] demonstrated inhibition of both factor Xa 
and thrombin by the venom of N. n. nigricinta. Whether the transient 
rise in the INR was the result of the direct toxic effects of the venom 
on the clotting cascade, or of disseminated intervascular coagulation 
secondary to rhabdomyolysis, needs further research.[22,33]
Additionally, the drowsiness and convulsion seen in our two younger 
patients may reflect neurotoxic symptoms due to the high venom­to­
mass ratio in smaller victims.[37]
Although the toxic composition of snake venom varies between 
species and even within the same species,[18,19,27] we hope that 
publishing these case studies will rekindle interest in and awareness 
of the systemic effects of envenomation by African spitting cobras, 
resulting in species­specific research.
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